SEC Comment Letter 0000000000-24-002778 to Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc.
Date: March 13, 2024 · CIK: 0001782303 · Accession: 0000000000-24-002778
AI Filing Summary & Sentiment
File numbers found in text: 333-277696
Letter
United States securities and exchange commission logo March 13, 2024 Zachary Hornby President and Chief Executive Officer Boundless Bio, Inc. 9880 Campus Point Drive, Suite 120 San Diego, CA 92121 Re:Boundless Bio, Inc. Registration Statement on Form S-1 Filed March 6, 2024 File No. 333-277696 Dear Zachary Hornby: We have reviewed your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe the comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 Management's Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies and Significant Estimates and Judgments Stock-Based Compensation Expense, page 96 1.Please refer to your letter submitted on March 8, 2024. Please explain why the preliminary fair values for the February 2024 grants were based upon a straight-line interpolation from the September 15, 2023 Valuation and not the more recent January 19, 2024 Valuation.
FirstName LastNameZachary Hornby Comapany NameBoundless Bio, Inc. March 13, 2024 Page 2 FirstName LastName Zachary Hornby Boundless Bio, Inc. March 13, 2024 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Ibolya Ignat at 202-551-3636 or Vanessa Robertson at 202-551-3649 if you have questions regarding comments on the financial statements and related matters. Please contact Daniel Crawford at 202-551-7767 or Alan Campbell at 202-551-4224 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew Bush, Esq.
Show Raw Text
United States securities and exchange commission logo
March 13, 2024
Zachary Hornby
President and Chief Executive Officer
Boundless Bio, Inc.
9880 Campus Point Drive, Suite 120
San Diego, CA 92121
Re:Boundless Bio, Inc.
Registration Statement on Form S-1
Filed March 6, 2024
File No. 333-277696
Dear Zachary Hornby:
We have reviewed your registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe the comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1
Management's Discussion and Analysis of Financial Condition and Results of Operations
Critical Accounting Policies and Significant Estimates and Judgments
Stock-Based Compensation Expense, page 96
1.Please refer to your letter submitted on March 8, 2024. Please explain why the preliminary
fair values for the February 2024 grants were based upon a straight-line interpolation from
the September 15, 2023 Valuation and not the more recent January 19, 2024 Valuation.
FirstName LastNameZachary Hornby
Comapany NameBoundless Bio, Inc.
March 13, 2024 Page 2
FirstName LastName
Zachary Hornby
Boundless Bio, Inc.
March 13, 2024
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Ibolya Ignat at 202-551-3636 or Vanessa Robertson at 202-551-3649 if
you have questions regarding comments on the financial statements and related matters. Please
contact Daniel Crawford at 202-551-7767 or Alan Campbell at 202-551-4224 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew Bush, Esq.